vs
大都会人寿（MET）与Insulet Corporation（PODD）财务数据对比。点击上方公司名可切换其他公司
Insulet Corporation的季度营收约是大都会人寿的1.3倍（$783.7M vs $600.0M），大都会人寿净利率更高（134.8% vs 13.0%，领先121.9%），Insulet Corporation同比增速更快（31.2% vs 7.9%），过去两年Insulet Corporation的营收复合增速更高（33.2% vs 2.0%）
大都会人寿（MetLife）是全球规模领先的保险、年金及员工福利服务提供商之一，创立于1868年，业务覆盖超60个国家和地区，服务约9000万客户，2018年位列《财富》美国500强营收排行榜第43位。
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
MET vs PODD — 直观对比
营收规模更大
PODD
是对方的1.3倍
$600.0M
营收增速更快
PODD
高出23.2%
7.9%
净利率更高
MET
高出121.9%
13.0%
两年增速更快
PODD
近两年复合增速
2.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $600.0M | $783.7M |
| 净利润 | $809.0M | $101.6M |
| 毛利率 | — | 72.6% |
| 营业利润率 | — | 18.7% |
| 净利率 | 134.8% | 13.0% |
| 营收同比 | 7.9% | 31.2% |
| 净利润同比 | -36.3% | 0.9% |
| 每股收益（稀释后） | $1.18 | $1.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收METPODD
| Q4 25 | $600.0M | $783.7M | ||
| Q3 25 | $621.0M | $706.3M | ||
| Q2 25 | $604.0M | $649.1M | ||
| Q1 25 | $611.0M | $569.0M | ||
| Q4 24 | $556.0M | $597.5M | ||
| Q3 24 | $554.0M | $543.9M | ||
| Q2 24 | $558.0M | $488.5M | ||
| Q1 24 | $577.0M | $441.7M |
净利润METPODD
| Q4 25 | $809.0M | $101.6M | ||
| Q3 25 | $896.0M | $87.6M | ||
| Q2 25 | $729.0M | $22.5M | ||
| Q1 25 | $945.0M | $35.4M | ||
| Q4 24 | $1.3B | $100.7M | ||
| Q3 24 | $1.3B | $77.5M | ||
| Q2 24 | $946.0M | $188.6M | ||
| Q1 24 | $867.0M | $51.5M |
毛利率METPODD
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% | ||
| Q1 24 | — | 69.5% |
营业利润率METPODD
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 11.2% | ||
| Q1 24 | — | 12.9% |
净利率METPODD
| Q4 25 | 134.8% | 13.0% | ||
| Q3 25 | 144.3% | 12.4% | ||
| Q2 25 | 120.7% | 3.5% | ||
| Q1 25 | 154.7% | 6.2% | ||
| Q4 24 | 228.6% | 16.9% | ||
| Q3 24 | 242.2% | 14.2% | ||
| Q2 24 | 169.5% | 38.6% | ||
| Q1 24 | 150.3% | 11.7% |
每股收益（稀释后）METPODD
| Q4 25 | $1.18 | $1.42 | ||
| Q3 25 | $1.22 | $1.24 | ||
| Q2 25 | $1.03 | $0.32 | ||
| Q1 25 | $1.28 | $0.50 | ||
| Q4 24 | $1.75 | $1.38 | ||
| Q3 24 | $1.81 | $1.08 | ||
| Q2 24 | $1.28 | $2.59 | ||
| Q1 24 | $1.10 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.6B | — |
| 总债务越低越好 | — | $930.8M |
| 股东权益账面价值 | $28.4B | $1.5B |
| 总资产 | $745.2B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.61× |
8季度趋势，按日历期对齐
现金及短期投资METPODD
| Q4 25 | $25.6B | — | ||
| Q3 25 | $26.2B | — | ||
| Q2 25 | $27.5B | — | ||
| Q1 25 | $26.9B | — | ||
| Q4 24 | $25.2B | — | ||
| Q3 24 | $26.4B | — | ||
| Q2 24 | $24.6B | — | ||
| Q1 24 | $24.7B | — |
总债务METPODD
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
股东权益METPODD
| Q4 25 | $28.4B | $1.5B | ||
| Q3 25 | $28.9B | $1.4B | ||
| Q2 25 | $27.7B | $1.5B | ||
| Q1 25 | $27.5B | $1.3B | ||
| Q4 24 | $27.4B | $1.2B | ||
| Q3 24 | $30.9B | $1.1B | ||
| Q2 24 | $27.3B | $998.4M | ||
| Q1 24 | $28.5B | $790.7M |
总资产METPODD
| Q4 25 | $745.2B | $3.2B | ||
| Q3 25 | $719.7B | $3.0B | ||
| Q2 25 | $702.5B | $3.5B | ||
| Q1 25 | $688.3B | $3.5B | ||
| Q4 24 | $677.5B | $3.1B | ||
| Q3 24 | $705.0B | $3.0B | ||
| Q2 24 | $675.7B | $2.9B | ||
| Q1 24 | $677.6B | $2.6B |
负债/权益比METPODD
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.1B | $183.3M |
| 自由现金流经营现金流 - 资本支出 | — | $48.2M |
| 自由现金流率自由现金流/营收 | — | 6.2% |
| 资本支出强度资本支出/营收 | — | 17.2% |
| 现金转化率经营现金流/净利润 | 8.75× | 1.80× |
| 过去12个月自由现金流最近4个季度 | — | $377.7M |
8季度趋势，按日历期对齐
经营现金流METPODD
| Q4 25 | $7.1B | $183.3M | ||
| Q3 25 | $3.6B | $125.7M | ||
| Q2 25 | $2.2B | $196.5M | ||
| Q1 25 | $4.3B | $63.8M | ||
| Q4 24 | $4.6B | $147.7M | ||
| Q3 24 | $4.2B | $98.5M | ||
| Q2 24 | $3.5B | $96.5M | ||
| Q1 24 | $2.3B | $87.6M |
自由现金流METPODD
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M | ||
| Q1 24 | — | $65.5M |
自由现金流率METPODD
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% | ||
| Q1 24 | — | 14.8% |
资本支出强度METPODD
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% | ||
| Q1 24 | — | 5.0% |
现金转化率METPODD
| Q4 25 | 8.75× | 1.80× | ||
| Q3 25 | 3.98× | 1.43× | ||
| Q2 25 | 3.00× | 8.73× | ||
| Q1 25 | 4.51× | 1.80× | ||
| Q4 24 | 3.63× | 1.47× | ||
| Q3 24 | 3.11× | 1.27× | ||
| Q2 24 | 3.69× | 0.51× | ||
| Q1 24 | 2.69× | 1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MET
| Other | $165.0M | 28% |
| Prepaidlegalplansandadministrativeonlycontracts | $158.0M | 26% |
| Vision Fee For Service Arrangements | $140.0M | 23% |
| Administrative Service | $76.0M | 13% |
| Distribution Service | $36.0M | 6% |
| Feebasedinvestmentmanagementservices | $25.0M | 4% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
